Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Zunsemetinib, CDD-450, Zumsemetinib
ATI-450 · 5 trials · 6 indications
Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP. Model-based estimates and 95% confidence intervals (CIs) were produced.
AN count was the sum of number of abscess and inflammatory nodules across anatomical regions. The least square (LS) mean change from baseline in the count at Week 12 was estimated from the Mixed Model Repeated Measures (MMRM) model.
Safety and tolerability reported as Adverse Events (AEs). AEs will be coded with the Medical Dictionary for Regulatory Activities (MedDRA) version 23.0. AEs will be presented by system organ class and preferred term in frequency tables.
| Arm | Type | Description |
|---|---|---|
| ATI-450 20 mg BID plus Methotrexate | EXPERIMENTAL | ATI-450 20 mg oral tablet twice daily (BID) with a stable weekly dose of methotrexate for 12 weeks |
| ATI-450 50 mg BID plus Methotrexate | EXPERIMENTAL | ATI-450 50 mg oral tablet BID with a stable weekly dose of methotrexate for 12 weeks |
| Placebo plus Methotrexate | PLACEBO_COMPARATOR | Placebo oral tablet BID with a stable weekly dose of methotrexate for 12 weeks |
| ATI-450 | EXPERIMENTAL | ATI-450 50 milligrams (mg) oral tablet twice daily (BID) |
| Placebo | EXPERIMENTAL | Placebo oral tablet BID |
| ATI-450 plus Methotrexate | EXPERIMENTAL | ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate |
| Dose escalation phase (zunsemetinib + mFOLFIRNOX) | EXPERIMENTAL | The dose of zunsemetinib will be determined by the dose level assigned and will be taken by mouth either once or twice daily depending on assigned dose level. mFOLFIRINOX will be 85 mg/m\^2 of oxaliplatin intravenous (IV) on day 1 of each cycle, 150 mg/m\^2 of irinotecan IV on day 1 of each cycle, 400 mg/m\^2 of leucovorin IV on day 1 of each cycle, and 2400 mg/m\^2 continuous infusion starting on day 1 of each cycle and continuing for 46 hours. Each cycle is 2 weeks in length. |
| Dose expansion phase (zunsemetinib + mFOLFIRNOX) | EXPERIMENTAL | The dose of zunsemetinib will be determined during the dose escalation phase of the trial. mFOLFIRINOX will be 85 mg/m\^2 of oxaliplatin intravenous (IV) on day 1 of each cycle, 150 mg/m\^2 of irinotecan IV on day 1 of each cycle, 400 mg/m\^2 of leucovorin IV on day 1 of each cycle, and 2400 mg/m\^2 continuous infusion starting on day 1 of each cycle and continuing for 46 hours. Each cycle is 2 weeks in length. |
| Phase Ib: Zunsemetinib + Capecitabine | EXPERIMENTAL | Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose along with capecitabine (1000 mg/m\^2 PO BID on Days 1-14 an every 21-day cycle). For patients enrolled in phase Ib, capecitabine is dosed on days 2-15 during cycles 1-2. Dose escalation of zunsemetinib will utilize a 3+3 design. A maximum of 3 dose levels of zunsemetinib will be tested, and the two highest dose levels which did not lead to more than 1 of 6 patients with DLT in cycle 1 will be chosen as the RP2D-L1 and RP2D-L2 for Phase II. If only one dose level of zunsemetinib was found tolerable, then only one RP2D will be chosen for Phase II. |
| Phase II Arm 1: Standard of care anti-resorptive + Capecitabine | ACTIVE_COMPARATOR | Standard of care anti-resorptives will consist of bisphosphonate (zoledronic acid) is to be administered every 4-12 weeks, or denosumab is to be administered every 4-6 weeks, as per physician choice and institutional practice. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3. |
| Phase II Arm 2: Zunsemetinib (RP2D-L1) + Capecitabine | EXPERIMENTAL | Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3. |
| Phase II Arm 3: Zunsemetinib (RP2D-L2) + Capecitabine | EXPERIMENTAL | Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3. If only one dose level of zunsemetinib plus capecitabine was found tolerable in phase Ib testing, the phase II trial will proceed with 2:1 two-arm randomization with Arm 2 of capecitabine plus zunsemetinib and Arm 1 of capecitabine plus standard of care anti-resorptive agent. |
| Name | Type | Description |
|---|---|---|
| ATI-450 50 mg oral tablet BID | DRUG | Oral, small molecule MK2 inhibitor |
| Placebo oral tablet | DRUG | Placebo tablet manufactured to match ATI-450 in appearance |
| Methotrexate | DRUG | 15 mg to 25 mg weekly |
| ATI-450 20 mg oral tablet BID | DRUG | Oral, small molecule MK2 inhibitor |
| ATI-450 | DRUG | Oral, small molecule MK2 inhibitor |
| Zunsemetinib | DRUG | Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water. |
| mFOLFIRINOX | DRUG | Includes oxaliplatin, irinotecan, leucovorin, and 5-FU. |
| Zumsemetinib | DRUG | Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water. |
| Capecitabine | DRUG | Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal. |
| Zoledronic acid | DRUG | Standard of care. Will receive zoledronic acid or denosumab. |
| Denosumab | DRUG | Standard of care. Will receive zoledronic acid or denosumab. |
Inclusion Criteria: * Able to comprehend and be willing to sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved participant ICF prior to administration of any study-related procedures. * Diagnosis of adult-onset RA as defined by the 2010 American College of Rheumato...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib, Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | povorcitinib, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Remibrutinib, Secukinumab |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE2 | Duvakitug, Brivekimig, SAR445399 |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Olatorepatide |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY072 |
| Oruka Therapeutics, Inc. | ORKA | 1 | PHASE2 | ORKA-002 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE1 | SAR447971 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE1 | Soquelitinib |
ATI-450 is an investigational oral small molecule being studied for the treatment of moderate to severe hidradenitis suppurativa and moderate to severe active rheumatoid arthritis. It has been evaluated in Phase 2 clinical trials in both indications, including studies where it was added to methotrexate in patients with rheumatoid arthritis.
ATI-450 targets JAK3, a kinase enzyme involved in immune signaling. By inhibiting JAK3, ATI-450 is designed to modulate inflammatory pathways. This mechanism underlies its investigation in inflammatory conditions such as rheumatoid arthritis and hidradenitis suppurativa.
ATI-450 is being developed by Aclaris Therapeutics, Inc., which trades on the Nasdaq under the ticker ACRS. The company is responsible for the clinical development program of ATI-450 in hidradenitis suppurativa and rheumatoid arthritis.
ATI-450 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in rheumatoid arthritis and one in hidradenitis suppurativa, and is not currently approved by the FDA for any indication.
ATI-450 has been studied in three completed Phase 2 trials: NCT05279417 in rheumatoid arthritis with 251 participants, NCT05216224 in hidradenitis suppurativa with 95 participants, and NCT04247815 in rheumatoid arthritis with 25 participants. All trials were randomized, double-blind, and controlled.